Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL
Recruiting · NCT06880913 · Registry updated 2026-03-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Nanobody-Based CD19/CD22 Tandem Dual CAR-T Therapy for R/R B-ALL | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, hematologic disorder, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Recruiting | Phase 1 / Phase 2 | 2026-03-30 | NCT06880913 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Hebei Senlang Biotechnology Inc., Ltd. | 14 |
| Peking University People's Hospital | 269 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Deparment of Hematology, Peking University People's Hospital | Beijing | China | 2 |